Areas of Focus
- Chemical Biology
- Medicinal Chemistry
- Targeting Key Transcription Factors in Antitumor Pharmacology
Work Experience
- 2022.12-present: Professor, Doctoral Supervisor, Key Laboratory of Regulatory Biology, East China Normal University
- 2015.12-2022.12: Researcher, Doctoral Supervisor, Key Laboratory of Regulatory Biology, East China Normal University
- 2009.12-2015.12: Associate Professor, Key Laboratory of Regulatory Biology, East China Normal University
Academic Background & Achievements
- 1997-2001: Bachelor in Chemistry, Nanchang University
- 2001-2006: PhD in Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Supervisor: Nan Fajun
- 2006-2009: Postdoctoral Research in Medicinal Chemistry, University of Illinois at Chicago, Collaborative Supervisor: Alan P. Kozikowski
Publications
- Discovery of a Potent and Oral Complex I OXPHOS Inhibitor that Abrogates Tumor Growth and Circumvents MEKi Resistance, Yihua Chen et al., 2023
- Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer, Yihua Chen et al., 2023
- Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer, Yihua Chen et al., 2023
- Current Advances of Small Molecule E3 Ligands for Proteolysis-Targeting Chimeras Design, Yihua Chen et al., 2023
- A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer, Yihua Chen et al., 2023
- Selectively targeting STAT3 using a small molecule inhibitor is a potential therapeutic strategy for pancreatic cancer, Yihua Chen et al., 2023
- Discovery of YH677 as a cancer stemness inhibitor for suppressing triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway, Yihua Chen et al., 2023
- Small-Molecule Modulators Targeting SHP2 for Cancer Therapy, Yihua Chen et al., 2023
- Recent advances in small molecule and peptide inhibitors of glucose-regulated protein 78 for cancer therapy, Yihua Chen et al., 2023
- A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia, Yihua Chen et al., 2023
- Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphoma, Yihua Chen et al., 2023
- Targeting Key Proteins involved in Transcriptional Regulation for Cancer Therapy: Current Strategies and Future Prospective, Yihua Chen et al., 2022
- Discovery of 2-Amino-3-cyanothiophene Derivatives as Potent STAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis, Yihua Chen et al., 2022
- Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr705/Ser727 Inhibitory Activity for Gastric Cancer Treatment, Yihua Chen et al., 2022
- Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer treatment, Yihua Chen et al., 2022
- B‑cell lymphoma 6 inhibitors: current advances and prospects of drug development for diffuse large B-cell lymphomas, Yihua Chen et al., 2022
- An instructive attempt on developing aptamer-constructed PROTAC for potential breast cancer treatment, Yihua Chen et al., 2022
- Discovery of 1,5-diaryl-1,2,4-triazole derivatives as MYOF inhibitors and its antitumor effects in pancreatic cancer, Yihua Chen et al., 2022
- Novel ortho-diphenyl-five-member N-hetero- aromatics compounds as potent anti-cancer cell agents, Yihua Chen et al., 2022
- The promising combination therapy strategy for overcoming resistance to histone deacetylase inhibitors in diffuse large B-cell lymphoma, Yihua Chen et al., 2022
- An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo, Yihua Chen et al., 2022
- A potent and selective small molecule inhibitor of myoferlin attenuates colorectal cancer progression, Yihua Chen et al., 2021
- Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Cancer Progression, Yihua Chen et al., 2020
- In vivo target protein degradation induced by PROTACs based on E3 ligase DCAF15, Yihua Chen et al., 2020
- Synthesis and Biological Evaluation of B‑Cell Lymphoma 6 Inhibitors of N-phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth, Yihua Chen et al., 2020
- Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma, Yihua Chen et al., 2020
- Design, synthesis and evaluation of phenylthiazole and phenylthiophene pyrimidindiamine derivatives targeting the bacterial membrane, Yihua Chen et al., 2020
- Synthesis and Biological Evaluation of Novel Thiophene-based N-bis-substituted Aromatic Amide Hydroxamic Acid Derivatives as Histone Deacetylase Inhibitors with Antitumor Activities, Yihua Chen et al., 2020
- An Emerging Therapeutic Approach by Targeting Myoferlin (MYOF) for Malignant Tumors, Yihua Chen et al., 2020
- Research on Function and Mechanisms of a Novel Small Molecule WG449E for Hypertrophic Scar, Yihua Chen et al., 2020
- Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin, Yihua Chen et al., 2019
- Design, synthesis and evaluation of hybrid of tetrahydrocarbazole with 2,4-diaminopyrimidine scaffold as antibacterial agents, Yihua Chen et al., 2019
- Discovery of Potent Ureido Tetrahydrocarbazole Derivatives for Cancer Treatments through targeting Tumor-associated Macrophages, Yihua Chen et al., 2019
- Small Molecule PROTACs: An Emerging Technology for Targeted Therapy in Drug Discovery, Yihua Chen et al., 2019
- Recent Advances of Small Molecular Regulators Targeting G Protein-Coupled Receptors Family for Oncology Immunotherapy, Yihua Chen et al., 2019
- Next-Generation of Selective Histone Deacetylase Inhibitors, Yihua Chen et al., 2019
- Development of Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-substituted Aromatic Amides with Antitumor Activities, Yihua Chen et al., 2019
- Inhibition of CDC25B with WG-391D impedes the tumorigenesis of ovarian cancer, Yihua Chen et al., 2019
- A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer, Yihua Chen et al., 2018
- Inhibition of HDACs-EphA2 signaling Axis with WW437 demonstrates promising preclinical antitumor activity in breast cancer, Yihua Chen et al., 2018
Awards
- 18th Chinese Pharmaceutical Association - Servier Young Medicinal Chemist Award (2015)
- Excellent Mentor in the 6th China International 'Internet+' College Students Innovation and Entrepreneurship Competition, Shanghai Division (2020)
